Joseph Bowman
Family · Virginia Beach, VANPI 1508411760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 632 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lundbeck LLC$2K
- Collegium Pharmaceutical, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$840
- Pfizer$781
- Amgen$460
- plus $3K from 29 others
What the payments were for
- Food & beverage$10,741100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 169 | $2,540 |
| Lundbeck LLC | 100 | $1,758 |
| Collegium Pharmaceutical, Inc. | 50 | $1,071 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 54 | $840 |
| Pfizer | 56 | $781 |
| Amgen | 22 | $460 |
| Biohaven Pharmaceutical Holding Company Ltd. | 24 | $431 |
| Lilly USA, LLC | 14 | $251 |
| Teva Pharmaceuticals USA, Inc. | 9 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $213 |
| Biohaven Pharmaceuticals, Inc. | 11 | $185 |
| Arbor Pharmaceuticals, Inc. | 13 | $181 |
| Almatica Pharma LLC | 10 | $179 |
| Novartis | 9 | $168 |
| Upsher-smith Laboratories LLC | 9 | $166 |
| Idorsia Pharmaceuticals US Inc | 8 | $156 |
| Vertex | 6 | $146 |
| Impel Pharmaceuticals Inc. | 8 | $130 |
| Merz Pharmaceuticals, LLC | 4 | $103 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Scilex Pharmaceuticals Inc. | 6 | $96 |
| Redhill Biopharma Inc. | 4 | $76 |
| Averitas Pharma Inc. | 4 | $75 |
| Nevro Corp. | 2 | $59 |
| Merck | 4 | $57 |
| Tersera Therapeutics LLC | 2 | $49 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| Eisai Inc. | 3 | $37 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Boston Scientific | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $26 |
| Abbott | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
How this compares
$10,742 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 52 | $84,900 |
| Nurtec OdtRimegepant Sulfate | 31 | $54,808 |
| Fentanyl | 105 | $20,026 |
| Oxycodone Hcl | 512 | $19,790 |
| Xtampza ErOxycodone Myristate | 24 | $19,756 |
| UbrelvyUbrogepant | 12 | $13,261 |
| Morphine Sulfate ErMorphine Sulfate | 162 | $7,447 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 109 | $5,545 |
| Hydromorphone Hcl | 150 | $4,889 |
| Methadone Hcl | 99 | $4,293 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 120 | $4,040 |
| Lidocaine | 32 | $2,901 |
| Morphine Sulfate | 51 | $2,347 |
| Gabapentin | 124 | $1,929 |
| Pregabalin | 18 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $781 | $54,80831 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $1,071 | $19,75624 claims |
| AbbVieUbrelvy | $2,540 | $13,26112 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $26 | $2,34751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Virginia Beach
- Andrea CottonVirginia Beach$696K
- Rachel KingVirginia Beach$51K
- Laura JacksonVirginia Beach$22K
- Kim PhamVirginia Beach$13K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.